Jump to content

Cris

Member
  • Posts

    963
  • Joined

  • Last visited

Contact Methods

  • Website URL
    http://
  • ICQ
    0

Cris's Achievements

Newbie

Newbie (1/14)

0

Reputation

  1. ASTHMA MEDICATION & DELIVERY DEVICE REVIEW in relation to YOUNG CHILDREN and MARKET POTENTIAL OF FUNHALER ASTHMA SPACER DEVICE (by VISIOMED) BRIEF OVERVIEW OF NON-INHALED ASTHMA MEDICATIONS in relation to YOUNG CHILDREN Monoclonal Antibodies IgE binds to allergens and triggers the release of substances from mast cells that can cause inflammation. When IgE binds to mast cells, a cascade of allergic reaction can begin. Xolair prevents these antibodies from sending messages to the mast cells so those cells never get the signal to release the chemicals that cause the reaction. Drugs in the class of Monoclonal Antibodies: Xolair (Omalizumab) is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair has been shown to decrease the incidence of asthma exacerbations in these patients. Safety and efficacy have not been established in other allergic conditions. - blocks immunoglobulin E (IgE), an underlying cause of allergic asthma symptoms - recommended for those who continue to have asthma symptoms even though they are taking inhaled steroids (but Xolair is not a rescue medication) - clinical studies - 0.5% of patients developed cancer, 0.2% on placebo developed cancer (time frame - less than 1 year) for patients 12 years of age and above http://www.xolair.com/index.jsp http://www.xolair.com/patient/prescribing_info.jsp http://www.xolair.com/index.jsp by INJECTION QUOTE EXAMPLE - MONOCLONAL ANTIBODIES by INJECTION from Tanox website Xolaire (Tanox) - subcutaneous use (injection) Prescribing Info - Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 have not been established. http://www.gene.com/gene/common/inc/pi/xol...ntraindications Leukotriene Modifiers Leukotriene modifiers are the newest class of drugs for the treatment of asthma. Leukotrienes are chemical compounds that are released during the inflammatory process. They are chemical messengers that help protect the body against attacks by invaders. However, when they are a part of an allergic response, leukotrienes cause airway obstruction through smooth muscle contraction, mucous production, and swelling of the airways. Leukotriene modifiers block the action or production of leukotrienes, and subsequently inhibit the inflammatory process. Two types of leukotreine - based medications have been developed: leukotriene inhibitors that interfere with the actual synthesis of leukotrienes, and leukotriene antagonists that block the action of leukotrienes by interfering with receptor sites. Leukotriene modifiers are good for patients who don't respond well to other anti-inflammatory therapies. They are also finding increasing favor with physicians who treat asthma in children. They are not used to treat acute asthmatic attacks and are available only in tablet form. Drugs in the class of Leukotriene Modifiers: Montelukast - MONTELUKAST (Singulair®) helps to reduce asthma symptoms (coughing, wheezing, shortness of breath, or chest tightness) and control your asthma. It does not provide instant relief and cannot be used to treat a sudden asthma attack. It works only when used on a regular basis to help reduce inflammation and prevent asthma attacks. Montelukast is effective in adults and children. This drug is also helpful in improving seasonal allergies, like hay fever. Generic montelukast tablets or chewable tablets are not yet available. Montelukast chewable tablets are normally prescribed in children 2 years of age or older. TABLET BY MOUTH ZAFIRLUKAST (Accolate®) helps to reduce asthma symptoms (coughing, wheezing, shortness of breath, or chest tightness) and control your asthma. It does not provide instant relief and cannot be used to treat a sudden asthma attack. It works only when used on a regular basis to help reduce inflammation and prevent asthma attacks. Zafirlukast is effective in adults and older children. Generic zafirlukast tablets are not yet available. Take zafirlukast by mouth (i.e., swallowed) on an empty stomach. Contact your pediatrician or health care professional regarding the use of this medicine in children under the age of 5 years old. Special care may be needed. TABLET BY MOUTH QUOTE EXAMPLE - MONTELUKAST by TABLET SINGULAIR is a prescription medicine approved to help control asthma in adults and children as young as 12 months and to help relieve the symptoms of seasonal allergies in adults and children as young as 2 years. SINGULAIR should NOT be used for the fast relief of acute asthma attacks or to prevent or treat asthma made worse by exercise. You should still have rescue medication available and continue to take your other asthma medications unless your doctor tells you to stop. QUOTE EXAMPLE - ZAFIRLUKAST by TABLET ACCOLATE is a nonsteroidal tablet for the prevention and continuous treatment of asthma in adults and children 5 years of age and older, available only by prescription. ACCOLATE IS NOT FOR USE IN THE REVERSAL OF ACUTE ASTHMA ATTACKS. Common side effects for ACCOLATE included headache, infection and nausea in adults and headache and abdominal pain in children. Oral Beta-2 Agonists Beta-2 agonists work in a manner similar to adrenaline, opening airways and easing breathing. They work by binding with, and thus stimulating, beta-2 receptors that line the cell walls of the lungs and the bronchioles. The effect of the stimulation is to relax smooth muscles and widen the airways. Possible side effects to the Beta-2 agonists include shakiness, rapid heartbeat, and upset stomach. Oral beta2-agonists works in a similar fashion to inhaled beta2-agonists, but they may take longer to work than the inhaled formulation. Oral beta-agonists must be absorbed in the digestive tract and travel through the circulatory system before they begin working in the lungs, whereas the inhaled formulations go straight to the lungs. Drugs in the class Oral Beta-2 Agonists: ALBUTEROL (Proventil®, Ventolin®) is a bronchodilator, a medicine that opens up your air passages and makes you breathe easier. It is a medicine for patients with various lung problems such as asthma and chronic bronchitis. Generic albuterol oral syrup is available.Take albuterol oral syrup by mouth. Follow the directions on the prescription label. Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed. SYRUP BY MOUTH ALBUTEROL (Proventil®, Ventolin®) is a bronchodilator, a medicine that opens up your air passages and makes you breathe easier. It is a medicine for patients with various lung problems such as asthma or chronic bronchitis. Generic albuterol tablets and extended-release tablets are available. Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed. TABLET BY MOUTH METAPROTERENOL (Alupent®) can open up air passages and make breathing easier for people with various lung problems such as asthma. Generic metaproterenol tablets are available.Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed. TABLET BY MOUTH TERBUTALINE (Brethine®) is a bronchodilator, a medicine that opens up your air passages and makes breathing easier. It is a medicine for people with lung problems such as severe asthma and bronchospasm. Generic terbutaline tablets are available. Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed. TABLET BY MOUTH QUOTE EXAMPLE - ALBUTEROL by SYRUP Proventil Syrup The usual starting dose for children 6 to 12 years of age is 1 teaspoonful 3 to 4 times a day. The dosage should not exceed 3 teaspoonfuls 4 times a day. For children 2 to 6 years of age, the starting dose is 0.1 milligram per 2.2 pounds of body weight, to a maximum of 4 milligrams, 3 times a day. Special Warnings: The drug has been known to cause life-threatening bronchial spasms, especially with the first dose from a new canister or vial. There have also been rare reports of skin reddening and peeling in children taking albuterol syrup. EXAMPLE OF ALBUTEROL TABLETS Volmax (albuterol sulfate) Extended-Release Tablets Volmax® Extended-Release Tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. QUOTE EXAMPLE - METAPROTERENOL by TABLET The usual dose for children between the ages of 4 and 12 is 10 mg (1/2 tablet) 3 times a day. For children over 12 years old the usual dose is 20 mg (1 tablet ) 3 times a day. People taking Alupent® tablets orally may experience a greater incidence of unwanted effects as compared to those taking inhaled Alupent®. http://www.lung.ca/drugs/pages/16.html QUOTE EXAMPLE - TERBUTALINE by TABLET This medication is not recommended for use in children below 12 years of age. EXAMPLE - TERBUTALINE by INJECTION Brethine (injection) Indications and Usage Brethine is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. BRIEF OVERVIEW OF INHALED ASTHMA MEDICATIONS & DELIVERY DEVICES in relation to YOUNG CHILDREN Dry Powder Inhalers Because DPIs rely on the force of a person's inhalation in order to properly deliver the medication into the lungs, DPIs are not recommended for children under five, people with severe asthma or those suffering a severe attack. Nebulizers These breathing treatments usually take about 10-15 minutes and are given several times a day. Metered Dose Inhalers (MDI) and Spacers The MDI is a small aerosol canister in a plastic holder which delivers a burst of medication directly to the lungs. The preferred method of using an MDI is by using it with a device called a "spacer." A spacer is a tube that attaches to the inhaler. It holds the medication until you can breathe it in. This makes using the MDI easier and helps deposit the medication into the lungs better. Spacers also come with masks to be used by small children or anyone else that may not be able to breathe in correctly through a standard spacer. Medications delivered by MDI include Aerobid, Alupent, Atrovent, Azmacort, Combivent, Intal, Qvar, Serevent, Tilade and Vanceril. MARKET POTENTIAL OF FUNHALER ASTHMA SPACER DEVICE (by VISIOMED) There are numerous proven, widely-accepted, and widely-used asthma medications delivered by inhalation (including generic versions). Inhaled medications are reliant on efficient inhalation methods to ensure compliance with medication delivery directly to the lungs as intended. Inefficient inhalation (not drawing a deep enough breath) results in inefficient medication. For this reason nebulizers and spacers are recommended as an aid to medicating asthmatic children. A nebulizer is well-suited to aiding medication in children too young to manage a spacer either alone or with carer assistance. A nebulizer is a passive device that does not in itself teach children to inhale deeply, therefore; there remains a very real risk of inefficient inhalation. In addition, this time-consuming delivery method (about 10-15 minutes several times a day) is highly likely to become troublesome, inconvenient, and encounter rising levels of user-resistance. A spacer is well-suited and highly recommended to aid medication in children as soon as they are able to manage its use; either alone or with carer assistance. Whilst standard (unembellished) spacers may be less troublesome and more convenient than a nebulizer, there is still a risk children will not inhale sufficient medication deeply into the lungs. The Funhaler, a children's asthma spacer device was developed specifically to address the above shortcomings and ensure efficient compliance with medication delivery. Effectiveness of the Funhaler has been proven in clinical trials: 1) The Funhaler improved the medication technique of children by 60%. 2) 94% of parents preferred the Funhaler to a conventional spacer device. Asthma is in the news daily and often linked to successful research and drug development news. Whilst all advances are welcome, from this writer's research and perspective, developments appearing in the news are early results requiring further research or further trials and most are years from successful market realisation, therefore; in this writer's opinion the Funhaler is best-suited to aid asthma medication delivery in young children as soon as they are able to manage its use; either individually or with carer assistance. This means the world-wide market potential for the Funhaler from early in 2005 (in this writer's opinion and worth only what you paid for it here), is clearly substantial and protected (by patents). NB Patents secured to protect the Funhaler may provide a basis for additional applications and markets.
  2. Cris

    VSG

    ASTHMA MEDICATION & DELIVERY DEVICE REVIEW in relation to YOUNG CHILDREN and MARKET POTENTIAL OF FUNHALER ASTHMA SPACER DEVICE (by VISIOMED) BRIEF OVERVIEW OF NON-INHALED ASTHMA MEDICATIONS in relation to YOUNG CHILDREN Monoclonal Antibodies IgE binds to allergens and triggers the release of substances from mast cells that can cause inflammation. When IgE binds to mast cells, a cascade of allergic reaction can begin. Xolair prevents these antibodies from sending messages to the mast cells so those cells never get the signal to release the chemicals that cause the reaction. Drugs in the class of Monoclonal Antibodies: Xolair (Omalizumab) is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair has been shown to decrease the incidence of asthma exacerbations in these patients. Safety and efficacy have not been established in other allergic conditions. - blocks immunoglobulin E (IgE), an underlying cause of allergic asthma symptoms - recommended for those who continue to have asthma symptoms even though they are taking inhaled steroids (but Xolair is not a rescue medication) - clinical studies - 0.5% of patients developed cancer, 0.2% on placebo developed cancer (time frame - less than 1 year) for patients 12 years of age and above http://www.xolair.com/index.jsp http://www.xolair.com/patient/prescribing_info.jsp http://www.xolair.com/index.jsp by INJECTION QUOTE EXAMPLE - MONOCLONAL ANTIBODIES by INJECTION from Tanox website Xolaire (Tanox) - subcutaneous use (injection) Prescribing Info - Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 have not been established. http://www.gene.com/gene/common/inc/pi/xol...ntraindications Leukotriene Modifiers Leukotriene modifiers are the newest class of drugs for the treatment of asthma. Leukotrienes are chemical compounds that are released during the inflammatory process. They are chemical messengers that help protect the body against attacks by invaders. However, when they are a part of an allergic response, leukotrienes cause airway obstruction through smooth muscle contraction, mucous production, and swelling of the airways. Leukotriene modifiers block the action or production of leukotrienes, and subsequently inhibit the inflammatory process. Two types of leukotreine - based medications have been developed: leukotriene inhibitors that interfere with the actual synthesis of leukotrienes, and leukotriene antagonists that block the action of leukotrienes by interfering with receptor sites. Leukotriene modifiers are good for patients who don't respond well to other anti-inflammatory therapies. They are also finding increasing favor with physicians who treat asthma in children. They are not used to treat acute asthmatic attacks and are available only in tablet form. Drugs in the class of Leukotriene Modifiers: Montelukast - MONTELUKAST (Singulair®) helps to reduce asthma symptoms (coughing, wheezing, shortness of breath, or chest tightness) and control your asthma. It does not provide instant relief and cannot be used to treat a sudden asthma attack. It works only when used on a regular basis to help reduce inflammation and prevent asthma attacks. Montelukast is effective in adults and children. This drug is also helpful in improving seasonal allergies, like hay fever. Generic montelukast tablets or chewable tablets are not yet available. Montelukast chewable tablets are normally prescribed in children 2 years of age or older. TABLET BY MOUTH ZAFIRLUKAST (Accolate®) helps to reduce asthma symptoms (coughing, wheezing, shortness of breath, or chest tightness) and control your asthma. It does not provide instant relief and cannot be used to treat a sudden asthma attack. It works only when used on a regular basis to help reduce inflammation and prevent asthma attacks. Zafirlukast is effective in adults and older children. Generic zafirlukast tablets are not yet available. Take zafirlukast by mouth (i.e., swallowed) on an empty stomach. Contact your pediatrician or health care professional regarding the use of this medicine in children under the age of 5 years old. Special care may be needed. TABLET BY MOUTH QUOTE EXAMPLE - MONTELUKAST by TABLET SINGULAIR is a prescription medicine approved to help control asthma in adults and children as young as 12 months and to help relieve the symptoms of seasonal allergies in adults and children as young as 2 years. SINGULAIR should NOT be used for the fast relief of acute asthma attacks or to prevent or treat asthma made worse by exercise. You should still have rescue medication available and continue to take your other asthma medications unless your doctor tells you to stop. QUOTE EXAMPLE - ZAFIRLUKAST by TABLET ACCOLATE is a nonsteroidal tablet for the prevention and continuous treatment of asthma in adults and children 5 years of age and older, available only by prescription. ACCOLATE IS NOT FOR USE IN THE REVERSAL OF ACUTE ASTHMA ATTACKS. Common side effects for ACCOLATE included headache, infection and nausea in adults and headache and abdominal pain in children. Oral Beta-2 Agonists Beta-2 agonists work in a manner similar to adrenaline, opening airways and easing breathing. They work by binding with, and thus stimulating, beta-2 receptors that line the cell walls of the lungs and the bronchioles. The effect of the stimulation is to relax smooth muscles and widen the airways. Possible side effects to the Beta-2 agonists include shakiness, rapid heartbeat, and upset stomach. Oral beta2-agonists works in a similar fashion to inhaled beta2-agonists, but they may take longer to work than the inhaled formulation. Oral beta-agonists must be absorbed in the digestive tract and travel through the circulatory system before they begin working in the lungs, whereas the inhaled formulations go straight to the lungs. Drugs in the class Oral Beta-2 Agonists: ALBUTEROL (Proventil®, Ventolin®) is a bronchodilator, a medicine that opens up your air passages and makes you breathe easier. It is a medicine for patients with various lung problems such as asthma and chronic bronchitis. Generic albuterol oral syrup is available.Take albuterol oral syrup by mouth. Follow the directions on the prescription label. Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed. SYRUP BY MOUTH ALBUTEROL (Proventil®, Ventolin®) is a bronchodilator, a medicine that opens up your air passages and makes you breathe easier. It is a medicine for patients with various lung problems such as asthma or chronic bronchitis. Generic albuterol tablets and extended-release tablets are available. Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed. TABLET BY MOUTH METAPROTERENOL (Alupent®) can open up air passages and make breathing easier for people with various lung problems such as asthma. Generic metaproterenol tablets are available.Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed. TABLET BY MOUTH TERBUTALINE (Brethine®) is a bronchodilator, a medicine that opens up your air passages and makes breathing easier. It is a medicine for people with lung problems such as severe asthma and bronchospasm. Generic terbutaline tablets are available. Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed. TABLET BY MOUTH QUOTE EXAMPLE - ALBUTEROL by SYRUP Proventil Syrup The usual starting dose for children 6 to 12 years of age is 1 teaspoonful 3 to 4 times a day. The dosage should not exceed 3 teaspoonfuls 4 times a day. For children 2 to 6 years of age, the starting dose is 0.1 milligram per 2.2 pounds of body weight, to a maximum of 4 milligrams, 3 times a day. Special Warnings: The drug has been known to cause life-threatening bronchial spasms, especially with the first dose from a new canister or vial. There have also been rare reports of skin reddening and peeling in children taking albuterol syrup. EXAMPLE OF ALBUTEROL TABLETS Volmax (albuterol sulfate) Extended-Release Tablets Volmax® Extended-Release Tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. QUOTE EXAMPLE - METAPROTERENOL by TABLET The usual dose for children between the ages of 4 and 12 is 10 mg (1/2 tablet) 3 times a day. For children over 12 years old the usual dose is 20 mg (1 tablet ) 3 times a day. People taking Alupent® tablets orally may experience a greater incidence of unwanted effects as compared to those taking inhaled Alupent®. http://www.lung.ca/drugs/pages/16.html QUOTE EXAMPLE - TERBUTALINE by TABLET This medication is not recommended for use in children below 12 years of age. EXAMPLE - TERBUTALINE by INJECTION Brethine (injection) Indications and Usage Brethine is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. BRIEF OVERVIEW OF INHALED ASTHMA MEDICATIONS & DELIVERY DEVICES in relation to YOUNG CHILDREN Dry Powder Inhalers Because DPIs rely on the force of a person's inhalation in order to properly deliver the medication into the lungs, DPIs are not recommended for children under five, people with severe asthma or those suffering a severe attack. Nebulizers These breathing treatments usually take about 10-15 minutes and are given several times a day. Metered Dose Inhalers (MDI) and Spacers The MDI is a small aerosol canister in a plastic holder which delivers a burst of medication directly to the lungs. The preferred method of using an MDI is by using it with a device called a "spacer." A spacer is a tube that attaches to the inhaler. It holds the medication until you can breathe it in. This makes using the MDI easier and helps deposit the medication into the lungs better. Spacers also come with masks to be used by small children or anyone else that may not be able to breathe in correctly through a standard spacer. Medications delivered by MDI include Aerobid, Alupent, Atrovent, Azmacort, Combivent, Intal, Qvar, Serevent, Tilade and Vanceril. MARKET POTENTIAL OF FUNHALER ASTHMA SPACER DEVICE (by VISIOMED) There are numerous proven, widely-accepted, and widely-used asthma medications delivered by inhalation (including generic versions). Inhaled medications are reliant on efficient inhalation methods to ensure compliance with medication delivery directly to the lungs as intended. Inefficient inhalation (not drawing a deep enough breath) results in inefficient medication. For this reason nebulizers and spacers are recommended as an aid to medicating asthmatic children. A nebulizer is well-suited to aiding medication in children too young to manage a spacer either alone or with carer assistance. A nebulizer is a passive device that does not in itself teach children to inhale deeply, therefore; there remains a very real risk of inefficient inhalation. In addition, this time-consuming delivery method (about 10-15 minutes several times a day) is highly likely to become troublesome, inconvenient, and encounter rising levels of user-resistance. A spacer is well-suited and highly recommended to aid medication in children as soon as they are able to manage its use; either alone or with carer assistance. Whilst standard (unembellished) spacers may be less troublesome and more convenient than a nebulizer, there is still a risk children will not inhale sufficient medication deeply into the lungs. The Funhaler, a children's asthma spacer device was developed specifically to address the above shortcomings and ensure efficient compliance with medication delivery. Effectiveness of the Funhaler has been proven in clinical trials: 1) The Funhaler improved the medication technique of children by 60%. 2) 94% of parents preferred the Funhaler to a conventional spacer device. Asthma is in the news daily and often linked to successful research and drug development news. Whilst all advances are welcome, from this writer's research and perspective, developments appearing in the news are early results requiring further research or further trials and most are years from successful market realisation, therefore; in this writer's opinion the Funhaler is best-suited to aid asthma medication delivery in young children as soon as they are able to manage its use; either individually or with carer assistance. This means the world-wide market potential for the Funhaler from early in 2005 (in this writer's opinion and worth only what you paid for it here), is clearly substantial and protected (by patents). NB Patents secured to protect the Funhaler may provide a basis for additional applications and markets.
  3. http://www.ShareScene.com/html/emoticons/weirdsmiley.gif Doh! Kathy, just realised you've already posted 'The Buffalo Theory'. Guess I should have read through first. Thanks for the 'Women v Ladies' chuckle, and thanks to all for the funnies posted here http://www.ShareScene.com/html/emoticons/laughingsmiley.gif . They're a great way to start or end the working day. Cris
  4. Cris

    Membership

    http://www.ShareScene.com/html/emoticons/king.gif Congratulations on the new milestone! ps Whoever did the promo did a great job!
  5. Have a Bonza Christmas and thanks for spending your money at SuperMark One day while visiting with an Aussie friend, Jack says to him: "Mick, my elbow hurts like heck. I guess I better see a doctor while I'm here in Oz." "Maaate .... you don't havta spend that kinda dough," said Mick. "There's a new whizbang computer down at SuperMark. I was actually one of its programmers. It's beaut. You just toss in a urine sample and bob's yer uncle. The computer tells you what's wrong and what to do about it. Takes ten seconds and costs ten dollars ... faster and cheaper than doctors and no bullshit." Jack fills a small jar with a urine sample and takes it to SuperMark. He deposits ten dollars. The computer lights up and asks for the urine sample. Jack pours the sample into the slot and waits. Ten seconds later, the computer ejects a printout: . Maaate! ... you poor bugger, you've got friggin tennis elbow. . Soak it in warm water daily for a couple of weeks and she'll be ace in no time. Have a Bonza Christmas and thanks for spending your dough at SuperMark. That evening, while thinking how amazing this new Australian technology was, Jack began wondering if the computer could be fooled. He mixed some tap-water, a stool sample from Mick's dog, urine samples from his wife and daughter, and some semen into the mixture for good measure. Jack hurried back to SuperMark eager to check the results. He deposited ten dollars, poured in his concoction, and awaited the results. Ten seconds later the computer ejected another printout: . Maaate! ... the tap water's too hard. Tell the missus to use a water softener. . The dog's got ringworm. Piss him off or bath him with anti-fungal shampoo and keep your distance. . Shit! Your daughter's got a flamin drug habit. Whip her into rehab, soon. . Your wife's up the duff. You little ripper she's having twins! Crickey, they're not yours. . The lawyer's gonna cost you a packet. Grab a mate and go get pissed. . Maaate! ... if you don't stop bloody playin with yourself your elbow's never gonna get better. Have a Bonza Christmas and thanks for spending yer last razoo at SuperMark.
  6. http://www.ShareScene.com/html/emoticons/wub.gif Wishing you all a Christmas season filled with the love of family and friends, and a New Year full of hope and joy. Cris http://www.ShareScene.com/html/emoticons/wub.gif
  7. In reply to: kathy on Sunday 05/12/04 07:58pm Another great one Kathy. I'll be sharing it around!
  8. In reply to: floyd on Thursday 02/12/04 09:21am Only in Oz http://www.ShareScene.com/html/emoticons/laughingsmiley.gif
  9. QUOTE (Smartman_plc @ Wednesday 01/12/04 12:48pm) Smartman, Thanks for the candle tip. I'll carry one with me in the car just in case the temperature drops way down to 7 degrees http://www.ShareScene.com/html/emoticons/tongue.gif again next winter. Regards, Cris
  10. Cris

    VSG

    Change of Director's Interest Notice Name of Director Ian Keith Macpherson (Director & Chairman) Date of Change 25.11.04 Number Acquired 500,000 shares Value/Consideration 3.0022 cents per share ($15,011) Nature of Change Acquisition of shares on market No of Securities Held After Change 11,142,521 shares 1,799,892 Options (VSGO) Refer to ASX notice 26.11.04 to clarify/confirm accuracy and obtain further details
  11. Subject: Boyle's Law The following is supposedly an actual question given on University of Washington Chemistry mid-term. The answer by one student was so "profound" that the professor shared it with colleagues, via the Internet, which is, of course, why we now have the pleasure of enjoying it as well. Bonus Question: Is Hell exothermic (gives off heat) or endothermic (absorbs heat)? Most of the students wrote proofs of their beliefs using Boyle's Law (gas cools when it expands and heats when it is compressed) or some variant. One student, however, wrote the following: QUOTE First, we need to know how the mass of Hell is changing in time. So we need to know the rate at which souls are moving into Hell and the rate at which they are leaving. I think that we can safely assume that once a soul gets to Hell, it will not leave. Therefore, no souls are leaving. As for how many souls are entering Hell, let's look at the different Religions that exist in the world today. Most of these religions state that if you are not a member of their religion, you will go to Hell. Since there is more than one of these religions and since people do not belong to more than one religion, we can project that all souls go to Hell. With birth and death rates as they are, we can expect the number of souls in Hell to increase exponentially. Now, we look at the rate of change of the volume in Hell because Boyle's Law states that in order for the temperature and pressure in Hell to stay the same, the volume of Hell has to expand proportionately as souls are added. This gives two possibilities: 1. If Hell is expanding at a slower rate than the rate at which souls enter Hell, then the temperature and pressure in Hell will increase until all Hell breaks loose. 2. If Hell is expanding at a rate faster than the increase of souls in Hell, then the temperature and pressure will drop until Hell freezes over. So which is it? If we accept the postulate given to me by Teresa during my Freshman year that, "it will be a cold day in Hell before I sleep with you†and take into account the fact that I slept with her last night, then number 2 must be true, and thus I am sure that Hell is exothermic and has already frozen over. The corollary of this theory is that since Hell has frozen over, it follows that it is not accepting any more souls and is therefore, extinct... leaving only Heaven thereby proving the existence of a divine being. Which explains why, last night, Teresa kept shouting "Oh my God." THIS STUDENT RECEIVED THE ONLY "A"
  12. Cris

    VSG

    Change of Director's Interest Notice Name of Director Ian Keith Macpherson (Director & Chairman) Date of Change 23.11.04 Number Acquired 500,000 shares Value/Consideration 3.3 cents per share ($16,500) Nature of Change Acquisition of shares on market No of Securities Held After Change 10,642,521 shares 1,799,892 Options (VSGO) Refer to ASX notice 25.11.04 to clarify/confirm accuracy and obtain further details
  13. In reply to: LEGGY on Tuesday 23/11/04 06:44pm Still chuckling http://www.ShareScene.com/html/emoticons/laughingsmiley.gif
×
×
  • Create New...